Article Sidebar
Published:
Jan 11, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Local anesthetic effect and safety of ropivacaine oily solution
Abstract
Methods: After effecting nerve block in postoperative rats by injection of ROPOS near the sciatic nerve, the expression levels of sodium-potassium-chloride co-transporter 1 (NKCC1) and potassium-chloride co-transporter 2 (KCC 2) in the spinal dorsal horn, were assayed. The safety of ROPOS in beagle dogs was evaluated through subcutaneous injection.
Results: The duration of anesthetic effect of ROPOS was 5 times longer than that of ropivacaine hydrochloride injection. The analgesic effect occurred via downregulation of the expression of NKCC1. Dogs administered ROPOS had acute inflammatory reactions at the injection sites within 3 days, but they recovered after 14 days. No other toxic reactions were observed. The Tmax values for dogs subcutaneously injected with ROPOS at doses of 15, 30 and 60 mg/kg were 2.15 ± 3.09, 6.25 ± 9.62 and 14.85 ± 11.82 h; with the Cmax values of 0.78 ± 0.51, 1.35 ± 0.38 and 2.09 ± 0.53 µg/mL, while the AUC(0-48h) values were 15.88 ± 5.41, 31.46 ± 11.45 and 66.10 ± 17.81 h·µg/mL, respectively. The values of Tmax, Cmax and AUC(0-48h) were positively correlated with ROPOS dose.
Conclusion: Ropivacaine oily solution has a longer duration of local anesthetic effect than ropivacaine hydrochloride injection and it also possesses a good safety profile. The acute inflammatory reactions are noteworthy and will be further investigated in subsequent studies.
